FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Taclonex (calcipotriene and betamethone dipropionate) from LEO Pharma Inc., under NDA 022185. This action indica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Scalp Psoriasis

Drugs mentioned

• TACLONEX (calcipotriol and betamethone dipropionate)

Snippet

SUPPL AP for TACLONEX (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE)